- Home
- ITT vs JAZZ Comparison
ITT vs JAZZ Comparison
Compare ITT & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ITT | JAZZ |
|---|---|---|
| Founded | 1920 | 2003 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Fluid Controls | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.7B | 16.1B |
| IPO Year | 1994 | 2007 |
Fundamental Metrics
Financial Performance| Metric | ITT | JAZZ |
|---|---|---|
| Price | $195.98 | $252.86 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 14 |
| Target Price | $216.45 | ★ $217.57 |
| AVG Volume (30 Days) | ★ 850.9K | 624.1K |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | ★ 0.73% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | 0.89 | ★ 4.43 |
| Revenue | ★ $3,938,500,000.00 | $1,618,693,000.00 |
| Revenue This Year | $32.87 | $6.22 |
| Revenue Next Year | $9.78 | $7.68 |
| P/E Ratio | $216.81 | ★ $58.36 |
| Revenue Growth | ★ 8.48 | N/A |
| 52 Week Low | $163.30 | $105.00 |
| 52 Week High | $225.26 | $261.30 |
Technical Indicators
Market Signals| Indicator | ITT | JAZZ |
|---|---|---|
| Relative Strength Index (RSI) | 49.98 | 57.56 |
| Support Level | $179.09 | $222.49 |
| Resistance Level | $199.29 | N/A |
| Average True Range (ATR) | 5.39 | 7.00 |
| MACD | 0.13 | 0.30 |
| Stochastic Oscillator | 47.91 | 69.01 |
Price Performance
Historical ComparisonAbout ITT ITT Inc.
ITT began its journey as International Telephone & Telegraph in 1920. Through decades of acquisitions in the mid-1900s, ITT went from manufacturing telephone switching equipment to operating hotels, car rentals, insurance agencies, and bread bakeries. In 1995, the firm split into three separate entities, one of which is the ITT in current operation. After a few more spinoffs in 2011, today ITT Inc. sells automotive, industrial, and aerospace products such as brake pads, seals, pumps, valves, connectors, and regulators. It has operations around the globe with notable exposures to North America, Europe, and Asia.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.